Overall, these results suggested that elevated TEP levels in NSCLC plasma were associated with the increased frequency of circulating CD8+PD-L1+ effector T cells and perhaps also CD4+PD-L1+ T cells prior to treatment at baseline. This evidence concerns the gene CD4 and non-small cell lung carcinoma.